What is Octreotide?
Octreotide is a somatostatin-related medicine used in specialist endocrine and gastrointestinal care. Immediate- and long-acting preparations have different roles.
Biological role or research focus
Somatostatin-related hormone control.
Its use for specific hormone-secreting conditions does not imply a general wellness benefit.
Role reference: MedlinePlus · Octreotide ↗
Names you may encounter
Sandostatin
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Somatostatin analogue
- Main research area
- Hormone-related symptoms and selected tumors
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Octreotide ↗
Quick answers
- Is Octreotide FDA approved?
- Yes. Sandostatin (NDA 019667), Sandostatin LAR, Mycapssa oral capsules and Bynfezia pen for acromegaly and symptoms of carcinoid tumors and VIPomas. Source ↗
- Is Octreotide safe?
- Octreotide is an FDA-approved somatostatin analog; its label warns about gallstones, slow or irregular heart rhythms, swings in blood sugar and an underactive thyroid. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Octreotide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| PROMID (2009) | Human randomized trial | 85 patients with metastatic, well-differentiated midgut neuroendocrine tumors. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2009
PROMID
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
- Population / model
- 85 patients with metastatic, well-differentiated midgut neuroendocrine tumors.
- Study design
- Long-acting octreotide versus placebo; planned interim analysis.
- Main finding
- Median time to tumor progression was 14.3 versus 6 months, with a hazard ratio of 0.34.
- Limits & context
- Too few deaths had occurred for a confirmatory survival conclusion. Tumor-growth control and relief of hormone-related symptoms are distinct outcomes; tumor subtype remains central.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
69 registered studies name Octreotide as an intervention among the 100 most recently updated of 328 search results; 22 are recruiting or under way, 6 have not started recruiting yet, 31 completed and 10 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 69 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Octreotide. ↗
Neonatal network : NN · 2006 Sep-Oct · Journal Article, Review
Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases. ↗
Journal of veterinary internal medicine · 2024 Jan-Feb · Multicenter Study, Journal Article
Read available full text ↗
Octreotide in hyperinsulinism. ↗
The Annals of pharmacotherapy · 1997 Feb · Journal Article, Review
Octreotide and Octreotide-derived delivery systems. ↗
Journal of drug targeting · 2023 Jul · Journal Article, Review
Risks & interactions
Octreotide is an FDA-approved somatostatin analog; its label warns about gallstones, slow or irregular heart rhythms, swings in blood sugar and an underactive thyroid.
Safety is established by FDA labeling and long clinical use, mainly in acromegaly and hormone-secreting tumors. Gallbladder problems were very common in long-term users in trials. Data in pregnancy are limited.
Take extra care with: Heart or blood pressure problemsDiabetes or blood-sugar medicinesCancer, now or in the past
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Known allergy to octreotide or any ingredient
Interactions
- Cyclosporine: octreotide can lower its levels, risking transplant rejection
- Insulin and other diabetes medicines: blood sugar can go up or down
- Beta-blockers and other heart-slowing drugs: added slowing of the heart rate
- Bromocriptine: octreotide increases its levels
- Narrow-margin drugs cleared by CYP3A4, such as quinidine: may build up
- Lutetium Lu 177 dotatate: octreotide can interfere with this cancer treatment
Serious risks
- Gallstone complications such as cholecystitis, cholangitis or pancreatitis
- Heart block, very slow heart rate and other rhythm problems
- Low or high blood sugar, sometimes leading to diabetes
- Underactive thyroid
- Fatty stools and poor fat absorption (pancreatic exocrine insufficiency)
- Changes in vitamin B12 levels
Common side effects
- gallbladder sludge or gallstones
- slow heart rate
- diarrhea and loose stools
- nausea
- abdominal discomfort
- high blood sugar
- underactive thyroid
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Sandostatin (octreotide) prescribing information ↗
Key precautions
Gallbladder issues, glucose changes, digestive symptoms, and cardiac or thyroid considerations may require monitoring. The formulation and coexisting conditions affect the precautions.
Source: MedlinePlus · Octreotide ↗
Official product context · checked October 4, 2026
Blood-glucose changes, gallbladder symptoms, heart-rate changes, and thyroid-related effects appear in the medication information. A trial response should be considered alongside these product-specific precautions.
Source: MedlinePlus · Octreotide injection ↗
Regulatory status
- U.S. FDA approval
- Approved
Sandostatin (NDA 019667), Sandostatin LAR, Mycapssa oral capsules and Bynfezia pen for acromegaly and symptoms of carcinoid tumors and VIPomas. Generics available. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Medicine status & clinical context
Octreotide medicines are used in specified acromegaly, carcinoid-tumor symptom, and VIPoma settings. Immediate-release and long-acting products have different clinical roles; a study of one preparation does not establish equivalence of every octreotide product.
The medication reference describes acromegaly and symptoms associated with carcinoid tumors or VIP-secreting tumors. PROMID adds evidence about growth control in a specific midgut neuroendocrine-tumor population.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
It suppresses release of selected hormones and secretory signals. Clinical research separately measures hormone-related symptoms and tumor progression.
Source: MedlinePlus · Octreotide ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Its use for specific hormone-secreting conditions does not imply a general wellness benefit.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does longer time to progression mean longer survival was proven?
No. PROMID’s initial survival analysis was not confirmatory.
Source: MedlinePlus · Octreotide ↗
Does every formulation have the same instructions?
No. Immediate-release and long-acting products differ, and one product’s regimen cannot be inferred from another.
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
- MedlinePlus · Octreotide ↗
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
